ONKURE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ONKURE THERAPEUTICS, INC. (OKUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 63.00 thousand shares for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2024-11-07
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-09-30 was -566.97K shares.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-06-30 was 127.50K shares.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-03-31 was 502.46K shares.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2023-12-31 was 799.92K shares, a 692.38% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 981.58K shares, a 179.38% increase from fiscal 2022.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 351.34K shares, a 1729.41% increase from fiscal 2021.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2021 was 19.20K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2024-09-30 | -566.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -439.46K shares derived: sum of 2 quarters · filed 2024-11-07 | 63.00K shares 10-Q · filed 2024-11-07 | 862.91K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 127.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 629.96K shares 10-Q · filed 2024-08-13 | 1.43M shares derived: sum of 3 quarters · filed 2024-08-13 | 1.43M shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 502.46K shares 10-Q · filed 2024-05-07 | 1.30M shares derived: sum of 2 quarters · filed 2024-05-07 | 1.30M shares derived: sum of 3 quarters · filed 2024-05-07 | |
| 2023-12-31 | 799.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 799.92K shares derived: sum of 2 quarters · filed 2024-03-28 | 981.58K shares 10-K · filed 2024-03-28 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 181.66K shares 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | 181.66K shares 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | 100.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 130.99K shares derived: sum of 2 quarters · filed 2023-03-27 | 165.51K shares derived: sum of 3 quarters · filed 2023-03-27 | 351.34K shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 30.04K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 64.56K shares derived: sum of 2 quarters · filed 2022-11-08 | 250.39K shares 10-Q · filed 2022-11-08 | |
| 2022-06-30 | 34.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 220.35K shares 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | 185.83K shares 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 19.20K shares 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |